JSPR News and Press, Jasper Therapeutics Inc. From 10/19/25

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your...

JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper PR Newswire Faruqi & Faruqi, LLP Securities Litigati...

2025-10-13 14:35:33 ET Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your...

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper PR Newswire Faruqi & Faruqi, LLP Securities Litigation Partner Ja...

Law Offices of Howard G. Smith reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR ) securities b...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would lik...

Philadelphia, Pennsylvania--(Newsfile Corp. - September 25, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Jasper Therapeutics, Inc. (NASDAQ: JSPR). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the com...

The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...